New York State Teachers Retirement System Has $6.14 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

New York State Teachers Retirement System lowered its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,784 shares of the medical research company's stock after selling 4,446 shares during the quarter. New York State Teachers Retirement System owned 0.08% of Charles River Laboratories International worth $6,139,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock worth $1,136,938,000 after purchasing an additional 60,497 shares during the period. Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the period. Geode Capital Management LLC raised its position in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after purchasing an additional 14,787 shares during the period. Ariel Investments LLC raised its position in shares of Charles River Laboratories International by 18.9% during the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after purchasing an additional 169,640 shares during the period. Finally, Invesco Ltd. raised its position in shares of Charles River Laboratories International by 17.1% during the fourth quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock worth $190,910,000 after purchasing an additional 151,159 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

NYSE:CRL traded up $0.38 during trading hours on Wednesday, hitting $158.77. The company's stock had a trading volume of 653,948 shares, compared to its average volume of 1,030,553. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The company has a market capitalization of $7.80 billion, a P/E ratio of -244.26, a PEG ratio of 5.36 and a beta of 1.49. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The stock has a fifty day simple moving average of $143.11 and a 200-day simple moving average of $152.16.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the company earned $2.27 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of research analyst reports. Evercore ISI raised their price target on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their target price for the company from $150.00 to $200.00 in a research report on Wednesday. Mizuho dropped their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $174.54.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president directly owned 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).